Human recombinant interferonalpha-2b for management of idiopathic recurrent superficial pyoderma in dogs: a pilot study.
The oral use of human recombinant interferonalpha-2b at 1,000 IU/ml/day appeared to provide only a transient benefit as compared with placebo for management of idiopathic recurrent superficial pyoderma in dogs. Further investigation using a larger population of dogs is needed to determine whether interferon is effective for long-term treatment of this condition.
Thompson
Lori A
LA
Animal Allergy and Skin Disease Center, 6327 North Keystone Avenue, Indianapolis, IN, 46220, USA.
Grieshaber
Terry L
TL
Glickman
Larry
L
Glickman
Nita
N
D000284:Administration, Oral; D000818:Animals; D004283:Dog Diseases / Q000188:drug therapy* / Q000473:pathology; D004285:Dogs; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D010865:Pilot Projects; D011711:Pyoderma / Q000188:drug therapy / Q000662:veterinary*; D011994:Recombinant Proteins; D012008:Recurrence; D013207:Staphylococcal Skin Infections / Q000188:drug therapy / Q000662:veterinary*; D016896:Treatment Outcome
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins